三年财务造假终落幕，*ST长药面临退市维权开启

Group 1 - The core issue revolves around *ST Changyao's financial fraud, which has been ongoing for three years, leading to administrative penalties from the China Securities Regulatory Commission [1][3] - The company inflated its revenue by over 730 million yuan and profits by more than 160 million yuan from 2021 to 2023, with false revenue accounting for nearly 20% of total revenue at its peak [4][5] - In 2022, the inflated profits represented an alarming 88.23% of the total profit, indicating severe discrepancies in the company's financial reporting [5] Group 2 - In addition to financial fraud, *ST Changyao is also involved in serious non-operational fund occupation, with 180 million yuan occupied, representing 92.08% of the company's latest audited net assets [2][6] - The company’s subsidiaries provided collateral guarantees for related parties without following any approval procedures, jeopardizing the interests of minority shareholders [2][6] - Legal actions are underway against the company, with precedents of successful second-instance rulings for investors who suffered losses during specific periods [2][6]